Sign inJoin waitlistJoin the waitlist

PG

Patrick Grierson

Physician · Washington University School of Medicine

Credentials: · · · · ·

History

Washington University School of Medicine
2020–Present

Hematology and Medical Oncology
Washington University/B-JH/SLCH Consortium
2017–2020
Internal Medicine
Barnes-Jewish Hospital
2014–2017
Ohio State University College of Medicine
2010–2014
University of Wisconsin, Madison, WI
2006–2010

Research

Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2023 · 501 citations
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network · 2025 · 179 citations
IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma
Gastroenterology · 2022 · 54 citations

KL
Kian-Huat Lim
17 papers
Andrea Wang-Gillam
8 papers
BT
Benjamin Tan
6 papers
Marianna Ruzinova
6 papers
KP
Katrina Pedersen
5 papers
Manik Amin
4 papers
RS
Rama Suresh
4 papers
Carlos Corvera
3 papers
Christopher Willett
3 papers
David Bentrem
3 papers
DI
David Ilson
3 papers
HP
Haeseong Park
3 papers

Grants

Targeting Tumor Intrinsic and Extrinsic Survival Signaling to Overcome Resistance to Radiation Therapy in Pancreatic Cancer.
National Cancer Institute · R01
PI · $603.5K · Washington University
2026–2031

Clinical trials

Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer
Principal investigator · Not yet recruiting · Phase 2
Washington University School of Medicine
2026–2031
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Principal investigator · Recruiting · Phase 2
Washington University School of Medicine
2026–2030
ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
Principal investigator · Recruiting · Phase 1, Phase 2
Washington University School of Medicine
2026–2029
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
Principal investigator · Suspended · Phase 1
National Cancer Institute (NCI)
2023–2027